Ipsen, bioMérieux sign companion diagnostics pact

Ipsen and bioMérieux have created a global collaboration in theranostics with a focus on hormone-dependent cancers. The partnership emphasizes the companies' expertise in the emerging field of personalized medicine. The companies will identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors and pituitary tumors. BioMérieux got into the arena of molecular diagnostics in 2008 through the $60 million purchase of San Diego company AviaraDx. AviaraDx had developed methods of testing the molecular biology of a sample in order to diagnose cancer. Ipsen/bioMérieux release | News

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.